StockData
Artiva Biotherapeutics, Inc. logo

Artiva Biotherapeutics, Inc. (ARTV) stock

ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$3.77−0.09 (-2.33%)

Close on Nov 18, 2026Market cap $184.32MP/E –Yield –

Artiva Biotherapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Artiva Biotherapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$75.23M. For fiscal 2025 it was -$76.75M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$76.75M–
FY2024Dec 31, 2024-$55.03M–
FY2023Dec 31, 2023-$47.43M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$20.36M–
Q1 FY2026Mar 31, 2026-$20.95M–
Q4 FY2025Dec 31, 2025-$14.73M–
Q3 FY2025Sep 30, 2025-$19.20M–
Q2 FY2025Jun 30, 2025-$22.98M–
Q1 FY2025Mar 31, 2025-$19.84M–
Q4 FY2024Dec 31, 2024-$14.65M–
Q3 FY2024Sep 30, 2024-$11.61M–
Q2 FY2024Jun 30, 2024-$13.69M–
Q1 FY2024Mar 31, 2024-$15.09M–
Q4 FY2023Dec 31, 2023-$10.68M–
Q3 FY2023Sep 30, 2023-$10.75M–

More Artiva Biotherapeutics figures

See a number that looks wrong?